TII
12.8.2024 13:47:19 CEST | Business Wire | Press release
The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has released a new large language model in its Falcon series, the Falcon Mamba 7B. The new model is the no. 1 globally performing open source State Space Language Model (SSLM) in the world, as independently verified by Hugging Face.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240812019509/en/
UAE’s Technology Innovation Institute Revolutionizes AI Language Models With New Architecture (Photo: AETOSWire)
As the first SSLM for Falcon, it departs from prior Falcon models which all use a transformer-based architecture. This new Falcon Mamba 7B model is yet another example of the pioneering research the institute is conducting and the breakthrough tools and products it makes available to the community in an open source format.
H.E. Faisal Al Bannai, Secretary General of ATRC and Adviser to the UAE President for Strategic Research and Advanced Technology Affairs, said: “The Falcon Mamba 7B marks TII’s fourth consecutive top-ranked AI model, reinforcing Abu Dhabi as a global hub for AI research and development. This achievement highlights the UAE’s unwavering commitment to innovation.”
For transformer architecture models, Falcon Mamba 7B outperforms Meta’s Llama 3.1 8B, Llama 3 8B, and Mistral’s 7B on the newly introduced benchmarks from HuggingFace. Meanwhile for the other SSLMs, Falcon Mamba 7B beats all other open source models in the old benchmarks and it will be the be first model on HuggingFace’s new tougher benchmark leaderboard.
Dr. Najwa Aaraj, Chief Executive of TII, said: “The Technology Innovation Institute continues to push the boundaries of technology with its Falcon series of AI models. The Falcon Mamba 7B represents true pioneering work and paves the way for future AI innovations that will enhance human capabilities and improve lives.”
State Space models are extremely performant at understanding complex situations that evolve over time, such as a whole book. This is because SSLMs do not require additional memory to digest such large bits of information.
Transformer based models, on the other hand, are very efficient at remembering and using information they have processed earlier in a sequence. This makes them very good at tasks like content generation, however, because they compare every word with every other word, this requires significant computational power.
SSLMs can find applications in various fields such as estimation, forecasting, and control tasks. Similar to the transformer architecture models, they also excel in Natural Language Processing tasks and can be applied to machine translation, text summarization, computer vision, and audio processing.
Dr. Hakim Hacid, Acting Chief Researcher of the TII’s AI Cross-Center Unit, said: “As we introduce the Falcon Mamba 7B, I’m proud of the collaborative ecosystem of TII that nurtured its development. This release represents a significant stride forward, inspiring fresh perspectives and further fueling the quest for intelligent systems. At TII, we’re pushing the boundaries of both SSLM and transformer models to spark further innovation in generative AI.”
Falcon LLMs have been downloaded over 45 million times, proving the outstanding success of the models. Falcon Mamba 7B will be released under TII Falcon License 2.0, the permissive Apache 2.0-based software license which includes an acceptable use policy that promotes the responsible use of AI. More information on the new model can be found at FalconLLM.TII.ae.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812019509/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
